Bellerophon Therapeutics Inc. (NASDAQ:BLPH) shares were up 6.8% during trading on Thursday . The company traded as high as $2.10 and last traded at $2.03, with a volume of 442,134 shares trading hands. The stock had previously closed at $1.90.

Separately, Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research report on Monday, May 23rd.

The stock’s market capitalization is $24.93 million. The company’s 50-day moving average price is $1.86 and its 200 day moving average price is $2.10.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.54) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. On average, analysts expect that Bellerophon Therapeutics Inc. will post ($1.84) earnings per share for the current year.

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.